English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, and its mortality has risen to second place in cancer-related deaths (1,2). About 800,000 patients die each year from HCC, and more than 50% of new or fatal cases occur in China (3). Due to the imperceptible early symptoms, most patients have lost the optimal time for radical ablation or surgical resection at the time of diagnosis (1,3). According to the NCCN guidelines, transcatheter arterial chemoembolization (TACE) is the Original Article

translational cancer research

Hepatic fibrosis and short-term clinical efficacy after hepatic artery embolization for unresectable hepatocellular carcinoma using doxorubicin-eluting HepaSphere